JPWO2021016062A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021016062A5 JPWO2021016062A5 JP2022503413A JP2022503413A JPWO2021016062A5 JP WO2021016062 A5 JPWO2021016062 A5 JP WO2021016062A5 JP 2022503413 A JP2022503413 A JP 2022503413A JP 2022503413 A JP2022503413 A JP 2022503413A JP WO2021016062 A5 JPWO2021016062 A5 JP WO2021016062A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- seq
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims description 106
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 102000010956 Glypican Human genes 0.000 claims description 16
- 108050001154 Glypican Proteins 0.000 claims description 16
- 108050009388 Glypican-2 Proteins 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 4
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 201000005969 Uveal melanoma Diseases 0.000 claims description 4
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 4
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims description 4
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims description 4
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 208000030173 low grade glioma Diseases 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 4
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 4
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 4
- 208000002918 testicular germ cell tumor Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- -1 41BB (CD137) Proteins 0.000 claims description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 102000009438 IgE Receptors Human genes 0.000 claims description 2
- 108010073816 IgE Receptors Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000012642 immune effector Substances 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 208000007312 paraganglioma Diseases 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 201000003708 skin melanoma Diseases 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims 2
- 208000008732 thymoma Diseases 0.000 claims 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 201000003163 breast adenoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025068546A JP2025111569A (ja) | 2019-07-19 | 2025-04-18 | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876483P | 2019-07-19 | 2019-07-19 | |
| US62/876,483 | 2019-07-19 | ||
| PCT/US2020/042469 WO2021016062A1 (en) | 2019-07-19 | 2020-07-17 | Chimeric antigen receptors containing glypican 2 binding domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025068546A Division JP2025111569A (ja) | 2019-07-19 | 2025-04-18 | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541538A JP2022541538A (ja) | 2022-09-26 |
| JPWO2021016062A5 true JPWO2021016062A5 (https=) | 2023-06-23 |
| JP2022541538A5 JP2022541538A5 (https=) | 2023-06-23 |
Family
ID=71944420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503413A Pending JP2022541538A (ja) | 2019-07-19 | 2020-07-17 | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
| JP2025068546A Pending JP2025111569A (ja) | 2019-07-19 | 2025-04-18 | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025068546A Pending JP2025111569A (ja) | 2019-07-19 | 2025-04-18 | グリピカン２結合ドメインを含有するキメラ抗原受容体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220257653A1 (https=) |
| EP (1) | EP3999546A1 (https=) |
| JP (2) | JP2022541538A (https=) |
| CN (3) | CN120484131A (https=) |
| AU (1) | AU2020317009A1 (https=) |
| WO (1) | WO2021016062A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3139319A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| WO2023107898A1 (en) * | 2021-12-06 | 2023-06-15 | The Children's Hospital Of Philadelphia | Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices) |
| WO2025235598A1 (en) * | 2024-05-09 | 2025-11-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| WO1994002620A2 (en) | 1992-07-27 | 1994-02-03 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| EP0781343B1 (de) | 1994-09-08 | 2003-07-02 | Vision 7 GmbH | Retrovirale vektorhybride und deren verwendung zum gentransfer |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| JP6987068B2 (ja) * | 2015-11-09 | 2021-12-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 癌マーカーおよび治療標的としてのグリピカン２ |
| SG10202012157QA (en) * | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| EP3494135A1 (en) * | 2016-08-02 | 2019-06-12 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
| CN111683962B (zh) * | 2017-11-10 | 2025-05-16 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
| CN112585163B (zh) * | 2018-08-08 | 2025-03-25 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途 |
-
2020
- 2020-07-17 CN CN202510522686.9A patent/CN120484131A/zh active Pending
- 2020-07-17 CN CN202080052372.2A patent/CN114555807B/zh active Active
- 2020-07-17 AU AU2020317009A patent/AU2020317009A1/en active Pending
- 2020-07-17 EP EP20751027.2A patent/EP3999546A1/en active Pending
- 2020-07-17 WO PCT/US2020/042469 patent/WO2021016062A1/en not_active Ceased
- 2020-07-17 CN CN202510075685.4A patent/CN119925596A/zh active Pending
- 2020-07-17 JP JP2022503413A patent/JP2022541538A/ja active Pending
- 2020-07-17 US US17/597,580 patent/US20220257653A1/en active Pending
-
2025
- 2025-04-18 JP JP2025068546A patent/JP2025111569A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023123502A5 (https=) | ||
| JP2020517294A5 (https=) | ||
| JP7641967B2 (ja) | ヒト化ｃｌｄｎ１８．２抗体 | |
| JP7031810B2 (ja) | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| CN114072427A (zh) | 抗dll3嵌合抗原受体及其用途 | |
| TWI806961B (zh) | 抗pd-1/抗her2天然抗體結構樣異源二聚體形式雙特異抗體及其製備 | |
| RS62151B1 (sr) | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu | |
| RU2015122484A (ru) | Агенты для лечения экспрессирующих клаудин раковых заболеваний | |
| US20230080842A1 (en) | Tetravalent symmetric bispecific antibodies | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| CN114456269A (zh) | 一种新的pd-1单克隆抗体 | |
| JP2017504578A5 (https=) | ||
| JP2022551081A (ja) | 癌処置のための多重特異性結合タンパク質 | |
| CA3058009A1 (en) | Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof | |
| IL272103B1 (en) | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer | |
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| JP2024508672A (ja) | 新規抗ｃｄ２４抗体 | |
| JPWO2022133169A5 (https=) | ||
| JP2019505545A5 (https=) | ||
| CN117083301A (zh) | 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 | |
| JP2017509323A5 (https=) | ||
| JPWO2021184673A5 (https=) | ||
| CN118946587A (zh) | 抗pd-1单克隆抗体及其衍生物和用途 | |
| JP2025525313A (ja) | 抗体及びその用途 |